ASCO 2021: The science behind olaparib’s promise shown in the OlympiA early breast cancer trial 03 Jun 2021 The OlympiA trial results show the benefits of a targeted drug in patients with early-stage breast cancer and inherited BRCA mutations. We spoke to Chair of the OlympiA steering committee Professor Andrew Tutt about the landmark ICR research that underpins this major breakthrough. Find out more Show/Hide
“Being told I had the BRCA2 mutation effectively saved my life” – Tony’s story 23 Dec 2020 After both he and his sister were diagnosed with breast cancer, Tony Herbert decided to undergo genetic testing to see if he had a BRCA mutation. Here he talks about how the result may have saved his life. Find out more Show/Hide
Knowledge of BRCA2 gene is power 06 Mar 2019 This week marks 25 years since our researchers discovered the BRCA2 gene. Our Cancer Stories Officer, Lydia Brain, spoke to Davina Gardner – a survivor of ovarian and breast cancer – about being a BRCA2 gene mutation carrier and how it has affected her and her family. Find out more Show/Hide
“Here you really can make a difference” – Professor Chris Lord reflects on the biggest developments in his career so far 18 Oct 2018
ASCO 2017: BRCA-targeting drug olaparib offers hope for women with advanced breast cancer with inherited mutation 07 Jun 2017